Financial Review: Cerus (CERS) & Its Rivals

Cerus (NASDAQ:CERS – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Cerus to related companies based on the strength of its analyst recommendations, profitability, risk, earnings, dividends, valuation and institutional ownership.

Insider and Institutional Ownership

78.4% of Cerus shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 5.3% of Cerus shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cerus and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cerus -3.23% -10.44% -3.42%
Cerus Competitors -300.62% -179.55% -22.71%

Analyst Recommendations

This is a breakdown of recent ratings for Cerus and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cerus 1 1 3 0 2.40
Cerus Competitors 4302 10596 18377 837 2.46

Cerus presently has a consensus target price of $5.25, suggesting a potential upside of 164.48%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.30%. Given Cerus’ higher possible upside, equities research analysts clearly believe Cerus is more favorable than its competitors.

Earnings and Valuation

This table compares Cerus and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cerus $206.13 million -$15.63 million -66.17
Cerus Competitors $1.89 billion $136.85 million 5.95

Cerus’ competitors have higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Cerus has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Cerus’ competitors have a beta of 5.41, indicating that their average share price is 441% more volatile than the S&P 500.

Summary

Cerus competitors beat Cerus on 7 of the 13 factors compared.

About Cerus

(Get Free Report)

Cerus Corporation is a biomedical products company focused on improving the safety of blood components used for transfusions. Its primary offering is the INTERCEPT Blood System, which uses a pathogen-reduction process designed to inactivate a broad range of viruses, bacteria, parasites and white blood cells in donated blood components. INTERCEPT is used to process platelet and plasma components. Cerus also develops related processing devices and supplies for blood centers and transfusion services.

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.